There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

此外，近日GSK公布其RSV疫苗在预防60岁以上老年人3年（3个完整流行季）的保护效力，累积保护效力为63%，然而却呈现显著的下降趋势——从第1年的83%到第2年的56%再到第3年的48%，而Arexvy的初始效力在三款疫苗中已是佼佼者。

点击上方“Vaccine前研”，关注最新疫苗动态自21世纪伊始，呼吸道病毒乃全球致死率之主要因素，相关疫情屡屡发生，尤以近期之SARS-CoV-2大流行最为显著，其后果之严重令人扼腕。此外，呼吸道合胞病毒（RSV）与流感病毒等，亦持续侵袭个体之呼吸道 ...

GSK filed two lawsuits at the US District of Delaware on 15 October saying that Moderna’s mRNA vaccine product Spikevax ...

London: British drugmaker GlaxoSmithKline (GSK) sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its ...

Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA ...

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent ...

In addition, 7 heavyweight single-product vaccines, including mRNA RSV vaccine (respiratory syncytial virus vaccine) and mRNA shingles/herpes zoster vaccine, have completed the pre-applications ...